Medications Development of Stimulant Dependence

承包商应根据任务订单，在国家药物滥用研究所（NIDA）、治疗研究与开发部（DTR&D）的兴奋剂依赖性药物开发（MDS）计划下进行I期、II期或III期临床试验。这些研究中心将评价药物化合物治疗药物滥用的临床效用。具体地说，减少兴奋剂使用的药物化合物（即，可卡因和甲基安非他明）和预防复发。这些临床试验的结果可能会提交给FDA，以支持新药申请（NDA）的提交。该合同的主要重点将是临床试验，以评估候选化合物的临床药理学，疗效和安全性。

The Contractor shall, on a task order basis, conduct Phase I, II, or III clinical trials under the National Institute on Drug Abuse (NIDA), Division of Treatment Research and Development (DTR&D) program for ¿Medications Development of Stimulant Dependence (MDS)'. These sites will evaluate the clinical utility of pharmacotherapeutic compounds for the treatment of drug abuse. Specifically, pharmacotherapeutic compounds to reduce the use of stimulants (i.e., cocaine and methamphetamine) and prevent relapse will be investigated. The results of these clinical trials may be submitted to the FDA in support of New Drug Application (NDA) submissions. The major emphasis of this contract will be on clinical trials to evaluate the clinical pharmacology, efficacy and safety profiles of the candidate compounds.